Lazertinib mesylate monohydrateProduct ingredient for Lazertinib

Name: Lazertinib mesylate monohydrate
Drug Entry: Lazertinib

Lazertinib is an oral, third-generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).^2,3 Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations.¹ It was approved by the FDA on August 19, 2024.⁵ Lazertinib is used alone or in combination with other chemotherapeutic agents.⁴

See full entry for Lazertinib
Accession Number: DBSALT003556
Structure: MOL SDF PDB SMILES InChI
Structure for Lazertinib mesylate monohydrate (DBSALT003556)
Synonyms: 2-PROPENAMIDE, N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)-2-PYRIMIDINYL)AMINO)-4-METHOXY-2-(4-MORPHOLINYL)PHENYL)-, METHANESULFONATE, HYDRATE (1:1:1) / LAZERTINIB MESILATE HYDRATE / Lazertinib mesylate hydrate / N-[5-[[4-[4-[(Dimethylamino)methyl]-3- phenyl-1H-pyrazol-1-yl]pyrimidin-2-yl]amino]-4-methoxy-2-(morpholin-4- yl)phenyl]acrylamide methanesulfonate hydrate (1:1:1)